The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...

Please provide your email address to receive an email when new articles are posted on . AMX0114 was developed to target calpain-2, a driver of axonal neurodegeneration. A pending clinical trial will ...

New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for neurodegenerative ...

AMX0114 is an investigational antisense oligonucleotide targeting calpain-2, a calcium-activated protease believed to play a role in ALS disease progression. The Food and Drug Administration (FDA) has ...

- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS - Phase 1 LUMINA trial of AMX0114 underway; early ...

Long-term exposure to common air pollutants is associated with a higher risk of developing motor neuron disease (MND), as well as faster functional decline and poorer survival after diagnosis — even ...

Darin Nakakihara doesn’t remember much from the day that changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, ...

VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS ~ Designation enables an enhanced development ...

Darin Nakakihara doesn’t remember much from the day changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, and ...